May 13 |
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript
|
May 11 |
DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript
|
May 8 |
DiaMedica Therapeutics GAAP EPS of -$0.14 beats by $0.02
|
May 8 |
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
|
May 2 |
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
|
May 1 |
Bullish DiaMedica Therapeutics Insiders Loaded Up On US$15.7m Of Stock
|
Apr 18 |
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
|
Apr 17 |
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
|